AstraZeneca-allied Eccogene targets early 2025 Nasdaq IPO with multiple NASH candidates
Eccogene, a Boston and Shanghai biotech working on an oral GLP-1 candidate with AstraZeneca, is considering an initial public offering early next year, CEO Jingye Zhou told Endpoints News.
The company is gearing up for multiple mid-stage tests in NASH, a form of fatty liver disease now known as metabolic dysfunction-associated steatohepatitis. The 40-employee biotech would likely raise a crossover round first and then eye a Nasdaq IPO in early 2025, Zhou said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
